Objective:To investigate the efficacy and prognosis of venetoclax combined with hypomethylating agents(HMAs)in the treatment of relapsed/refractory acute myeloid leukemia(AML).Methods:From June 2021 to February 2022,1...Objective:To investigate the efficacy and prognosis of venetoclax combined with hypomethylating agents(HMAs)in the treatment of relapsed/refractory acute myeloid leukemia(AML).Methods:From June 2021 to February 2022,14 patients with relapsed/refractory AML were treated with venetoclax combined with HMAs,among which nine patients were treated with venetoclax+azacytidine,while five patients were treated with venetoclax+decitabine.The efficacy of the treatments was observed,and the patients were followed up.Results:All patients received one to five courses of treatment,in which the median course of treatment was three;four cases achieved CR and another four achieved PR,with NR in six cases;there was no treatment-related death.There were seven deaths up to the end of the follow-up period,all of which were progressive deaths at the end of the disease,and the overall survival rate was 50.00%.All the patients experienced different degrees of nausea,vomiting,and myelosuppression(Grade Ⅱ–Ⅳ),nine patients had Grade 3–4 hematological adverse reactions,and seven patients had infection.Conclusion:Venetoclax combined with hypomethylating agents is effective in the treatment of relapsed/refractory AML,with good prognosis,and some patients may even achieve CR.Although bone marrow suppression is serious with this combination,it is well tolerated.展开更多
Objective: to explore the clinical treatment of critically ill MDS and elderly patients with acute myeloid leukemia in the formulation of treatment plan, azacytidine, low-dose cytarabine combined intervention measures...Objective: to explore the clinical treatment of critically ill MDS and elderly patients with acute myeloid leukemia in the formulation of treatment plan, azacytidine, low-dose cytarabine combined intervention measures on the treatment effect. Methods: 25 cases of critically ill MDS and elderly patients with acute myeloid leukemia in our hospital were selected and analyzed. The research time span was from May 2018 to October 2019. The patients were randomly divided into control group and observation group. There were 12 patients in the control group and 13 patients in the observation group. The patients in the control group were treated with azacytidine and the observation group were treated with azacytidine and low-dose cytarabine. The clinical effects of different treatment schemes were compared by comparing the effect of disease control of patients in groups. Results: after the completion of the course of treatment, the improvement degree of the observation group was better than that of the control group, and the total effective rate of the observation group was higher than that of the control group, and the difference between the two groups was statistically significant (P < 0.05). Conclusion: the combination of azacytidine and low-dose cytarabine in the treatment of critically ill MDS and elderly patients with acute myeloid leukemia has a satisfactory intervention effect on the condition of the disease and ensures the comfortable experience of the patients during the treatment, which is worthy of vigorous use in clinical practice and worthy of praise.展开更多
文摘Objective:To investigate the efficacy and prognosis of venetoclax combined with hypomethylating agents(HMAs)in the treatment of relapsed/refractory acute myeloid leukemia(AML).Methods:From June 2021 to February 2022,14 patients with relapsed/refractory AML were treated with venetoclax combined with HMAs,among which nine patients were treated with venetoclax+azacytidine,while five patients were treated with venetoclax+decitabine.The efficacy of the treatments was observed,and the patients were followed up.Results:All patients received one to five courses of treatment,in which the median course of treatment was three;four cases achieved CR and another four achieved PR,with NR in six cases;there was no treatment-related death.There were seven deaths up to the end of the follow-up period,all of which were progressive deaths at the end of the disease,and the overall survival rate was 50.00%.All the patients experienced different degrees of nausea,vomiting,and myelosuppression(Grade Ⅱ–Ⅳ),nine patients had Grade 3–4 hematological adverse reactions,and seven patients had infection.Conclusion:Venetoclax combined with hypomethylating agents is effective in the treatment of relapsed/refractory AML,with good prognosis,and some patients may even achieve CR.Although bone marrow suppression is serious with this combination,it is well tolerated.
文摘Objective: to explore the clinical treatment of critically ill MDS and elderly patients with acute myeloid leukemia in the formulation of treatment plan, azacytidine, low-dose cytarabine combined intervention measures on the treatment effect. Methods: 25 cases of critically ill MDS and elderly patients with acute myeloid leukemia in our hospital were selected and analyzed. The research time span was from May 2018 to October 2019. The patients were randomly divided into control group and observation group. There were 12 patients in the control group and 13 patients in the observation group. The patients in the control group were treated with azacytidine and the observation group were treated with azacytidine and low-dose cytarabine. The clinical effects of different treatment schemes were compared by comparing the effect of disease control of patients in groups. Results: after the completion of the course of treatment, the improvement degree of the observation group was better than that of the control group, and the total effective rate of the observation group was higher than that of the control group, and the difference between the two groups was statistically significant (P < 0.05). Conclusion: the combination of azacytidine and low-dose cytarabine in the treatment of critically ill MDS and elderly patients with acute myeloid leukemia has a satisfactory intervention effect on the condition of the disease and ensures the comfortable experience of the patients during the treatment, which is worthy of vigorous use in clinical practice and worthy of praise.
